CLX-0921

CLX-0921 is an orally active small molecule and a thiazolidinedione (TZD) derivative that acts as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It has been investigated for the treatment of type 2 diabetes mellitus due to its potent antihyperglycemic activity. Unlike commercially available TZDs such as rosiglitazone and pioglitazone, CLX-0921 is a weaker activator of PPARγ but maintains glucose-lowering efficacy comparable to rosiglitazone in vivo. Notably, it demonstrates significantly reduced adipogenic potential and increases glycogen synthesis in vitro—an effect not typically observed with other TZDs. The compound was derived from a natural product and has reached phase I clinical trials[3][4][2][1].

Other names

CLX-0921CLX0921CLX 0921THR-0921THR0921THR 09214LXSR6QYJI